Galectins—Potential Therapeutic Targets for Neurodegenerative Disorders
Authors:
- Sapana ChaudharySCSapana Chaudhary
- Sameer ChaudharySCSameer Chaudhary
- Sakshi RawatSRSakshi Rawat
- Archana KulkarniAKArchana Kulkarni
- Anwar L. BilgramiABAnwar L. Bilgrami
- Asma PerveenAPAsma Perveen
- Badrah S. AlghamdiBABadrah S. Alghamdi
- Torki Al ZughaibiTZTorki Al Zughaibi
- Ghulam Md AshrafGhulam Md Ashraf
- Mohammad Zubair AlamMAMohammad Zubair Alam
- Tabish HussainTHTabish Hussain
Open Access
- 20 September 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11012
Abstract
Advancements in medicine have increased the longevity of humans, resulting in a higher incidence of chronic diseases. Due to the rise in the elderly population, age-dependent neurodegenerative disorders are becoming increasingly prevalent. The available treatment options only provide symptomatic relief and do not cure the underlying cause of the disease. Therefore, it has become imperative to discover new markers and therapies to modulate the course of disease progression and develop better treatment options for the affected individuals. Growing evidence indicates that neuroinflammation is a common factor and one of the main inducers of neuronal damage and degeneration. Galectins (Gals) are a class of β-galactoside-binding proteins (lectins) ubiquitously expressed in almost all vital organs. Gals modulate various cellular responses and regulate significant biological functions, including immune response, proliferation, differentiation, migration, and cell growth, through their interaction with glycoproteins and glycolipids. In recent years, extensive research has been conducted on the Gal superfamily, with Gal-1, Gal-3, and Gal-9 in prime focus. Their roles have been described in modulating neuroinflammation and neurodegenerative processes. In this review, we discuss the role of Gals in the causation and progression of neurodegenerative disorders. We describe the role of Gals in microglia and astrocyte modulation, along with their pro- and anti-inflammatory functions. In addition, we discuss the potential use of Gals as a novel therapeutic target for neuroinflammation and restoring tissue damage in neurodegenerative diseases.Keywords
Funding Information
- Institutional Fund Projects (IFPDP-30-22)
This publication has 118 references indexed in Scilit:
- Galectin-3 Regulates Intracellular Trafficking of EGFR through Alix and Promotes Keratinocyte MigrationJournal of Investigative Dermatology, 2012
- Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics ApproachJournal of Proteome Research, 2010
- Inflammation in neurodegenerative diseasesImmunology, 2010
- Hypoxic-Ischemic Encephalopathy in the Term InfantClinics in Perinatology, 2009
- Galectin-8 Induces Apoptosis in Jurkat T Cells by Phosphatidic Acid-mediated ERK1/2 Activation Supported by Protein Kinase A Down-regulationJournal of Biological Chemistry, 2009
- Ligand Reduces Galectin-1 Sensitivity to Oxidative Inactivation by Enhancing Dimer FormationJournal of Biological Chemistry, 2009
- Galectin–glycan lattices regulate cell-surface glycoprotein organization and signallingBiochemical Society Transactions, 2008
- L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowthCurrent Opinion in Neurobiology, 2008
- Functions of cell surface galectin-glycoprotein latticesCurrent Opinion in Structural Biology, 2007
- Galectin-3 in apoptosis, a novel therapeutic targetJournal of Bioenergetics and Biomembranes, 2007